These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16948524)

  • 1. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study.
    Akgun H; Gonlusen G; Cartwright J; Suki WN; Truong LD
    Arch Pathol Lab Med; 2006 Sep; 130(9):1354-7. PubMed ID: 16948524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency.
    Ledneva E; Karie S; Launay-Vacher V; Janus N; Deray G
    Radiology; 2009 Mar; 250(3):618-28. PubMed ID: 19244037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can gadolinium be safely given in renal failure?
    Weissleder R
    AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
    [No Abstract]   [Full Text] [Related]  

  • 4. Gadolinium-induced nephrotoxicity.
    Buhaescu I; Izzedine H
    Int J Clin Pract; 2008 Jul; 62(7):1113-8. PubMed ID: 18218006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent.
    Fujisaki K; Ono-Fujisaki A; Kura-Nakamura N; Komune N; Hirakawa N; Tsuruya K; Komune S; Iida M
    Clin Nephrol; 2011 Mar; 75(3):251-4. PubMed ID: 21329636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
    Brillet G; Dubois M; Beaufils H; Bourbouze R; Deray G
    Invest Radiol; 1994 Mar; 29(3):352-4. PubMed ID: 8175311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast.
    Prince MR; Arnoldus C; Frisoli JK
    J Magn Reson Imaging; 1996; 6(1):162-6. PubMed ID: 8851422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.
    Sam AD; Morasch MD; Collins J; Song G; Chen R; Pereles FS
    J Vasc Surg; 2003 Aug; 38(2):313-8. PubMed ID: 12891113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vacuolization of tubules in gadolinium-associated acute renal failure.
    Riviello ED; Wang KC; Hochman ME; Sariban A; Da Rocha RC; Dogaru G; Christopher K
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(1):108-15. PubMed ID: 21491811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure.
    Haustein J; Niendorf HP; Krestin G; Louton T; Schuhmann-Giampieri G; Clauss W; Junge W
    Invest Radiol; 1992 Feb; 27(2):153-6. PubMed ID: 1601607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys.
    Elmståhl B; Nyman U; Leander P; Golman K; Chai CM; Grant D; Doughty R; Pehrson R; Björk J; Almén T
    Radiology; 2008 Apr; 247(1):88-97. PubMed ID: 18292474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-iodinated contrast media nephrotoxicity].
    Janus N; Launay-Vacher V; Deray G
    Nephrol Ther; 2018 Nov; 14(6):484-490. PubMed ID: 30301611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Neutrophil Gelatinase-Associated Lipocalin and Urinary Kidney Injury Molecule-1 as Potential Biomarkers of Subclinical Nephrotoxicity After Gadolinium-Based and Iodinated-Based Contrast Media Exposure in Pediatric Patients with Normal Kidney Function.
    Spasojević-Dimitrijeva B; Kotur-Stevuljević J; Đukić M; Paripović D; Miloševski-Lomić G; Spasojević-Kalimanovska V; Pavićević P; Mitrović J; Kostić M
    Med Sci Monit; 2017 Sep; 23():4299-4305. PubMed ID: 28874655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
    Briguori C; Colombo A; Airoldi F; Melzi G; Michev I; Carlino M; Montorfano M; Chieffo A; Bellanca R; Ricciardelli B
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):175-80. PubMed ID: 16400668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media.
    Murphy KJ; Hansen R; Prince MR
    AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574
    [No Abstract]   [Full Text] [Related]  

  • 16. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury.
    Kalb RE; Helm TN; Sperry H; Thakral C; Abraham JL; Kanal E
    Br J Dermatol; 2008 Mar; 158(3):607-10. PubMed ID: 18076707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
    Perazella MA
    Curr Drug Saf; 2008 Jan; 3(1):67-75. PubMed ID: 18690983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency.
    Rofsky NM; Weinreb JC; Bosniak MA; Libes RB; Birnbaum BA
    Radiology; 1991 Jul; 180(1):85-9. PubMed ID: 2052729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure.
    Naito S; Tazaki H; Okamoto T; Takeuchi K; Kan S; Takeuchi Y; Kamata K
    J Toxicol Sci; 2017; 42(3):379-384. PubMed ID: 28496044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.